Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.32 |
| ▸ | GPR6 | P46095 | 2/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670642 | 0.92 | KDM4E (0.32) | FAAHKDM4EGSK3BDYRK1A | |
| SCHEMBL19670501 | 0.88 | FAAH (0.35) | FAAHMLLT1SCDGSK3BDYRK1A | |
| SCHEMBL16754338 | 0.88 | ABL1 (0.38) | FAAHKDM4EMLLT1GPR6SCD | |
| SCHEMBL19361182 | 0.86 | FAAH (0.38) | FAAHKDM4EMLLT1GSK3B | |
| SCHEMBL19706066 | 0.85 | FAAH (0.35) | FAAHGSK3BDYRK1A | |
| SCHEMBL19670259 | 0.85 | FAAH (0.35) | FAAHGSK3BDYRK1A | |
| SCHEMBL19670616 | 0.85 | KDM4E (0.33) | FAAHKDM4EDYRK1A | |
| SCHEMBL16754578 | 0.84 | GPR6 (0.36) | FAAHGPR6 | |
| SCHEMBL19699702 | 0.84 | GPR6 (0.36) | FAAHGPR6 | |
| SCHEMBL17618624 | 0.84 | GSK3B (0.39) | FAAHGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FAAH 1077/4885KDM4E 1355/4885MLLT1 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.